A Phase 3 interventional study of TAS-102 and Placebo in Colorectal Cancer, sponsored by Taiho Oncology, Inc.. Completed at 115 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-09-19.
Sponsored by Taiho Oncology, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Colorectal Neoplasms by Otsuka Holdings Co., Ltd. — 1 open to participants now, 1 under way, none of them phase 3. Colorectal Neoplasms · Otsuka Holdings Co., Ltd..
Among the 16 studies in Colorectal Neoplasms by Otsuka Holdings Co., Ltd., this one is the 3rd largest by enrollment of the 13 interventional ones that give a count, is the only one that started in 2012, is one of 4 in phase 3, and was the 9th registered.
6,552 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.
Browse Colorectal Neoplasms studies →1 of the 16 studies in Colorectal Neoplasms by Otsuka Holdings Co., Ltd. is open now, in 1 country. Recruiting first, the newest first:
Taiho Pharmaceutical Co., Ltd. · Sites in Japan
Ages 18+
By country, each count listing its studies:
Of the 1,178 Colorectal Neoplasms studies recruiting now, 761 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 8 · Phase 3 5
First in 1996; this study’s year is marked. 1 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 800 is above the median of 76 across 4,809 interventional studies indexed under Colorectal Neoplasms.
Median enrollment 107 across the 13 interventional studies, 12 across the 1 observational. Of the 13 that completed or were terminated, 6 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Taiho Oncology, Inc., one of the names counted as Otsuka Holdings Co., Ltd.. Under that name alone:
Taiho Oncology, Inc. is the lead sponsor of 66 studies on the registry; 9 are open to participants now.
Of its 25 completed or terminated interventional studies of FDA-regulated products, 13 (52%) have results posted.
1 of the studies in Colorectal Neoplasms by Otsuka Holdings Co., Ltd. that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04999761Taiho Pharmaceutical Co., Ltd.AB122 Platform Study | 2027-06 |
Add it to your calendar (.ics) → With an account.
Among the 16 studies in Colorectal Neoplasms by Otsuka Holdings Co., Ltd., from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to compare the efficacy and safety of TAS-102 versus placebo in patients with refractory metastatic colorectal cancer.
This is a multinational, double-blind, two-arm, parallel, randomized Phase 3 comparison study evaluating the efficacy and safety of TAS-102 versus placebo in patients with refractory metastatic colorectal cancer. Patients will be randomly assigned (2:1) to TAS-102 (experimental arm) or placebo (control arm).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: TAS-102
Drug: Placebo
35 mg/m2/dose, orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria are met.
Placebo tablets, orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria are met.
Overall Survival
Overall survival was defined as the time from the date of randomization to the date of death for participants. If a participant discontinued study medication for reasons other than radiologic disease progression, the participant was followed for tumor response until radiologic disease progression or initiation of new anticancer therapy.
Time frame: Every 8 weeks, up to 12 months after the last participant was randomized or until the target number of events (deaths) was met, whichever was later. (Overall survival data was collected till 24 Jan 2014 which was date of observation of the 571st death)
Progression-free Survival
Tumor assessments were performed throughout the study based on RECIST, Version 1.1, 2009. Progression free survival was defined as the time (in months) from the date of randomization until the date of the investigator-assessed radiological disease progression or death due to any cause. For participants who were alive with no radiological disease progression as of the analysis cut-off date, their survival was censored at the date of the last tumor assessment. Participants who received non-study cancer treatment before disease progression, or participants with clinical but not radiologic evidence of progression, were censored at the date of the last radiologic evaluable tumor assessment before the non-study cancer treatment was initiated.
Time frame: Every 8 weeks, up to 12 months after the last participant was randomized or until the date of the investigator-assessed radiological disease progression or death due to any cause,whichever was later. (Progression free survival cutoff: 31 Jan 2014)
Percentage of Participants With Adverse Events (AE), Treatment-Related AEs, Discontinuations, Serious Adverse Events (SAEs) and Deaths
An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment-related AEs were events between administration of study drug and up to 30 Days that were absent before treatment or that worsened relative to pre-treatment state. A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability /incapacity; congenital anomaly. The AEs were graded for severity using National Cancer Institute Common Terminology Criteria for AEs.
Time frame: From the time of signing the informed consent form until the period of participant follow up (30 days following after the administration of last dose of study medication or until initiation of new antitumor therapy, whichever was earlier
This was a multicenter study conducted in 101 study centers in 13 countries including the United States, Japan, Spain, Italy, Germany, Belgium, France, Australia, United Kingdom, Austria, Ireland, Sweden, and Czech Republic.
| Milestone | TAS-102 | Placebo |
|---|---|---|
| Started | 534 | 266 |
| Treated | 533 | 265 |
| Completed | 162 | 51 |
| Not completed | 372 | 215 |
| Withdrew: Not treated | 1 | 1 |
| Withdrew: Death | 367 | 211 |
| Withdrew: Lost to follow-up | 3 | 3 |
| Withdrew: Participant refusal | 1 | 0 |
Overall survival was defined as the time from the date of randomization to the date of death for participants. If a participant discontinued study medication for reasons other than radiologic disease progression, the participant was followed for tumor response until radiologic disease progression or initiation of new anticancer therapy.
| months | TAS-102 | Placebo |
|---|---|---|
| Overall Survival | 7.1 (6.5 to 7.8) | 5.3 (4.6 to 6.0) |
Tumor assessments were performed throughout the study based on RECIST, Version 1.1, 2009. Progression free survival was defined as the time (in months) from the date of randomization until the date of the investigator-assessed radiological disease progression or death due to any cause. For participants who were alive with no radiological disease progression as of the analysis cut-off date, their survival was censored at the date of the last tumor assessment. Participants who received non-study cancer treatment before disease progression, or participants with clinical but not radiologic evidence of progression, were censored at the date of the last radiologic evaluable tumor assessment before the non-study cancer treatment was initiated.
| months | TAS-102 | Placebo |
|---|---|---|
| Progression-free Survival | 2.0 (1.9 to 2.1) | 1.7 (1.7 to 1.8) |
An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment-related AEs were events between administration of study drug and up to 30 Days that were absent before treatment or that worsened relative to pre-treatment state. A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability /incapacity; congenital anomaly. The AEs were graded for severity using National Cancer Institute Common Terminology Criteria for AEs.
| percentage of participants | TAS-102 | Placebo |
|---|---|---|
| Any adverse event (AE) | 98.3 | 93.2 |
| Any treatment-related AE | 85.7 | 54.7 |
| Any ≥Grade 3 AE | 69.4 | 51.7 |
| Any treatment-related ≥Grade 3 AE | 49.0 | 9.8 |
| Any serious AE (SAE) | 29.6 | 33.6 |
| Any AE resulting in discontinuation | 10.3 | 13.6 |
| Any AE with outcome of death | 3.2 | 11.3 |
Collected over From the time of signing the informed consent form until the period of participant follow up (30 days following the administration of last dose of study medication or until initiation of new anti-tumor therapy, whichever was earlier, up to 85 weeks approximately (duration of study)).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| TAS-102 | 17/533 (3.2%) | 158/533 (29.6%) | 506/533 (94.9%) |
| Placebo | 30/265 (11.3%) | 89/265 (33.6%) | 227/265 (85.7%) |
| Event | TAS-102 | Placebo |
|---|---|---|
| General physical health deteriorationGeneral disorders | 15/533 | 11/265 |
| Febrile neutropeniaBlood and lymphatic system disorders | 14/533 | 0/265 |
| Hepatic failureHepatobiliary disorders | 3/533 | 6/265 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 3/533 | 6/265 |
| Abdominal painGastrointestinal disorders | 8/533 | 5/265 |
| IleusGastrointestinal disorders | 3/533 | 5/265 |
| Decreased appetiteMetabolism and nutrition disorders | 3/533 | 5/265 |
| AnaemiaBlood and lymphatic system disorders | 10/533 | 0/265 |
| VomitingGastrointestinal disorders | 7/533 | 0/265 |
| AscitesGastrointestinal disorders | 3/533 | 3/265 |
| Event | TAS-102 | Placebo |
|---|---|---|
| NauseaGastrointestinal disorders | 256/533 | 63/265 |
| Decreased appetiteMetabolism and nutrition disorders | 206/533 | 76/265 |
| AnaemiaBlood and lymphatic system disorders | 205/533 | 22/265 |
| FatigueGeneral disorders | 185/533 | 60/265 |
| DiarrhoeaGastrointestinal disorders | 167/533 | 33/265 |
| NeutropeniaBlood and lymphatic system disorders | 152/533 | 0/265 |
| Neutrophil count decreasedInvestigations | 148/533 | 1/265 |
| White blood cell count decreasedInvestigations | 146/533 | 1/265 |
| VomitingGastrointestinal disorders | 142/533 | 38/265 |
| AstheniaGeneral disorders | 96/533 | 29/265 |
Analysis was performed in Intent-to-Treat (ITT) population which included all randomized participants.
| Age, Categorical(Participants) | TAS-102 | Placebo | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 300 | 148 | 448 |
| >=65 years | 234 | 118 | 352 |
| Age, Continuous(years) | TAS-102 | Placebo | Total |
|---|---|---|---|
| Mean | 61.5 ± 10.21 | 61.5 ± 10.51 | 61.5 ± 10.30 |
| Sex: Female, Male(Participants) | TAS-102 | Placebo | Total |
|---|---|---|---|
| Female | 208 | 101 | 309 |
| Male | 326 | 165 | 491 |
Showing the first 100 of 115 sites across 13 countries. Choose a country and city above to see the rest.
Ran from Jun 2012 to primary completion in Jan 2014, 19 months.
Results were first posted in May 2019, 5 years 3 months after primary completion.
Of 69 industry-sponsored phase 3 interventional studies under Colorectal Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 54. This study's 19 months is below that.
Counting every sponsor, half of 175 studies reached it within 50 months; a quarter within 35 and three quarters within 79.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.